Clinical trials: Acute Myelogenous Leukemia (AML)
Leukemia
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005793
- Testing
- Cytarabine, Daunorubicin, Etoposide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Lymphoma
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00004114
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia, Acute Myeloid Leukemia
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
This is a single-arm, single-dose dose-escalation and dose-expansion study.
- Trial name
- NCT06347458
- Testing
- BG1805
- Volunteers
- 24 people
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Acute Myeloid Leukemia in Children
Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test
Acute myeloid leukemia (AML) accounts for about 15% to 20% of childhood leukemia, but the death rate accounts for about 50%. About 20-30% of children with AML did not achieve complete response (CR) after 2 induction treatments…
- Trial name
- NCT06233526
- Testing
- Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Acute Myeloid Leukemia (AML)
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care.
- Trial name
- NCT05144243
- Testing
- Venetoclax, Azacitidine
- Where
- 18 sites in China
- Volunteers
- 44 people
- Sponsor
- AbbVie
Childhood Cancer, Acute Lymphoblastic Leukemia
Quality of Life in Children With Cancer
Childhood cancers cover a wide range of diseases; leukemia, central nervous system cancers and lymphomas are the most common ones among them.
- Conditions
- Childhood Cancer, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- sıcc (NCT03190499)
- Testing
- Family based assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people
- Sponsor
- Cumhuriyet University
Acute Myeloid Leukemia (AML)
A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia
This randomized, open label, multi arm phase II trial will evaluate the efficacy and safety of venetoclax based induction regimens of varying intensity (VA, VAM, or 2+5+V) versus standard 3+7 in fit patients aged ≥14 years with…
- Trial name
- NCT07754799
- Testing
- Daunorubicin, Cytarabine, Liposome Mitoxantrone
- Volunteers
- 320 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia (AML)
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults.
- Trial name
- NCT04813263
- Where
- 281 sites in Japan
- Volunteers
- 424 people
- Sponsor
- AbbVie
Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
This pilot study has been designed to investigate the safety of pembrolizumab treatment for disease relapse following allogeneic stem cell transplant (alloSCT).
- Conditions
- Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02981914
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Leukemia
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006084
- Testing
- lintuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have locally advanced or metastatic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004258
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Hematologic Malignancies
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with…
- Trial name
- NCT00741455
- Testing
- Stem Cell Transplant, G-CSF, Fludarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Acute Myeloid Leukemia (Relapsed/Refractory)
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor combined with chidamide in the treatment of unfit R/R AML.
- Trial name
- NCT05951855
- Testing
- Selinexor, Chidamide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia
The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML).
- Trial name
- Diamond-01 (NCT03008187)
- Testing
- MEN1703
- Where
- 15 sites in United States, Italy and 2 more
- Volunteers
- 73 people
- Sponsor
- Menarini Group
Acute Myeloid Leukemia
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia
This study will test the effectiveness and safety of Venetoclax in combination with standard induction regimen for patients with acute leukemia and poor prognosis.
- Trial name
- V-FIRST (NCT03455504)
- Testing
- Venetoclax
- Where
- 22 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Leukemia
Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML
Patients with refractory and relapse leukemia had poor outcome even with allogeneic stem cell transplantation. In our previous retrospective study, the overall survival is 14.6+/-8.8% while 90% patients eventually relapsed with…
- Trial name
- NCT01496547
- Testing
- intensive chemo - RIC preparation
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
AML (Acute Myeloid Leukemia)
DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML
Protocol Title: A Prospective, Randomized Controlled Study of Venetoclax Plus 3-Day Decitabine (DEC3-VEN) Versus Venetoclax Plus "2+6" DA Versus "3+7" DA Regimen in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)…
- Trial name
- NCT07712848
- Testing
- Arm A (VEN+"2+6"DA), Arm B (DEC3-VEN), Arm C ("3+7"DA)
- Where
- China
- Volunteers
- 291 people
- Sponsor
- The Second Affiliated Hospital of Kunming Medical University
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
AML and MDS-EB2 are malignancies of the bone marrow. The standard treatment for these diseases is chemotherapy. Patients participating have a special type of this disease because the leukemia cells (blasts) have developed an…
- Trial name
- HOVON150AML (NCT03839771)
- Testing
- AG-120, AG-221
- Where
- 181 sites in Australia, Austria and 13 more
- Volunteers
- 968 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
AML Therapy With Irradiated Allogeneic Cells
This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT02105116
- Testing
- fludarabine phosphate, cytarabine, donor lymphocytes
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Rutgers, The State University of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.